P&G launches five-minute whitening: Procter & Gamble will support its new five-minute home-use whitening strips, Crest Whitestrips Daily Multicare, with a national marketing campaign advertising "The Brightest Five Minutes of Your Day," the firm says. The campaign will feature print ads in April publications, TV ads breaking March 26, a consumer promotion and branded Web sites, according to P&G. Crest Whitestrips Daily Multicare are the first to whiten in five-minute applications by removing surface stains and protecting teeth from everyday stain buildup, the company says. If consumers whiten everyday for five minutes, then the rate of whitening is higher than the rate of stain formation and stains do not have time to accumulate, P&G claims. The new strips retail at $39.99 for 42 applications, with each pouch now containing one upper and one lower strip for added convenience and portability, P&G says. Crest Whitestrips debuted in 2001; the line currently comprises four variations - Classic, Premium, Premium Plus and Renewal...
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
Monitoring the use of decentralized elements in clinical trials is a priority for the European medicines regulatory network.
Pfizer told the Pink Sheet it would work with the health technology assessment institute, NICE, with the hope of making Hympavzi available to patients with hemophilia A via the National Health Service.
The verdict by the Unified Patent Court in the dispute between Sanofi/Regeneron Pharmaceuticals and Amgen explains what companies should look out for when deciding whether infringement has taken place when it comes to second medical use patents.
